Dr. James Anthony Ellingford is the company’s executive director.
The pinnacle of his professional career was serving as president of a worldwide, publicly traded, $1 billion company with offices in Geneva, Switzerland, and New York, USA.
He has a wealth of expertise working internationally and has successfully built strong relationships with several governments and financial organisations throughout the globe.
Dr. Ellingford has a doctorate in management, a master’s degree in business administration, and a postgraduate degree in corporate management.
Dr. Ellingford, who has a deep interest in ethics and governance, also teaches MBA students at a prestigious Sydney university about corporate governance.
Who or what is Creso Pharma?
In Europe, the Middle East, North America, and the Asia Pacific, Creso Pharma Limited develops, registers, and commercialises pharmaceutical-grade cannabis, hemp-based nutraceutical products, and treatments for human and animal health. The business creates and markets therapeutic treatments, cultivates, processes, and distributes cannabis-based products, and provides cannabis-related retail goods. Aside from cannaDOL, a CBD-based topical gel paired with a blend of cooling and warming essential oils, the company’s products include anibidiol, a complementary feed item for pets, cannaQIX, a nutraceutical product containing hemp oil extract, vitamins, and zinc, and cannaQIX, which reduces stress and supports psychological and nervous functions. Australia’s Nedlands serves as the corporate headquarters for Creso Pharma Limited, which was founded in 2015.